Laboratory Medicine ›› 2023, Vol. 38 ›› Issue (2): 190-195.DOI: 10.3969/j.issn.1673-8640.2023.02.018
Previous Articles Next Articles
WU Jiong1, HU Jiahua1, SHI Meifang2, LIU Tao2, DAI Jie2, LU Xinyi3, ZOU Zheng2(
)
Received:2022-01-14
Revised:2022-07-08
Online:2023-02-28
Published:2023-04-17
CLC Number:
WU Jiong, HU Jiahua, SHI Meifang, LIU Tao, DAI Jie, LU Xinyi, ZOU Zheng. Research progress of biomarkers of prostate cancer[J]. Laboratory Medicine, 2023, 38(2): 190-195.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2023.02.018
| 项目 | 样本类型 | 指标 |
|---|---|---|
| 筛查和诊断 | ||
| PSA | 血液 | PSA |
| PHI | 血液 | PHI=p2PSA /游离PSA×（总PSA）1/2 |
| 4K评分 | 血液 | 基于总PSA、游离PSA、iPSA、hK2和患者临床参数计算 |
| PCA3 | 尿液 | 尿液外泌体中PCA3表达 |
| 精选 MDx | 尿液 | 尿液HOXC6 mRNA和DLX1 mRNA水平 |
| 外泌体智能积分 | 尿液 | 尿液外泌体mRNA |
| Prostarix积分 | 尿液 | 尿液肌氨酸、丙氨酸、甘氨酸和谷氨酸水平 |
| TMPRSS2-ERG | 尿液 | TMPRSS2-ERG融合产物 |
| 风险分层 | ||
| AR-V7 | 血液 | CTC中的AR-V7 |
| 基因组前列腺积分 | 前列腺活检组织 | 17个基因组合 |
| Prolaris积分 | 前列腺活检组织 | 46个基因的RNA表达 |
| Decipher积分 | 前列腺活检组织 | 17个基因组成的积分系统 |
| ProMark积分 | 前列腺活检组织 | 8个蛋白类标志物（GUL2、DERL1、FUS、HSPA9、PDSS2、pS6、SMAD4、YBX1） |
| 治疗药物相关 | ||
| CTC | 血液 | 根据CTC的不同物理或生物特征进行分离 |
| ctDNA | 血液 | 全外显子或全基因组测序分析特定突变 |
| ctDNA | 血液 | TP53突变、DDR基因等靶向基因测序 |
| ctDNA | 血液 | 采用ddPCR检测AR突变和拷贝数 |
| 项目 | 样本类型 | 指标 |
|---|---|---|
| 筛查和诊断 | ||
| PSA | 血液 | PSA |
| PHI | 血液 | PHI=p2PSA /游离PSA×（总PSA）1/2 |
| 4K评分 | 血液 | 基于总PSA、游离PSA、iPSA、hK2和患者临床参数计算 |
| PCA3 | 尿液 | 尿液外泌体中PCA3表达 |
| 精选 MDx | 尿液 | 尿液HOXC6 mRNA和DLX1 mRNA水平 |
| 外泌体智能积分 | 尿液 | 尿液外泌体mRNA |
| Prostarix积分 | 尿液 | 尿液肌氨酸、丙氨酸、甘氨酸和谷氨酸水平 |
| TMPRSS2-ERG | 尿液 | TMPRSS2-ERG融合产物 |
| 风险分层 | ||
| AR-V7 | 血液 | CTC中的AR-V7 |
| 基因组前列腺积分 | 前列腺活检组织 | 17个基因组合 |
| Prolaris积分 | 前列腺活检组织 | 46个基因的RNA表达 |
| Decipher积分 | 前列腺活检组织 | 17个基因组成的积分系统 |
| ProMark积分 | 前列腺活检组织 | 8个蛋白类标志物（GUL2、DERL1、FUS、HSPA9、PDSS2、pS6、SMAD4、YBX1） |
| 治疗药物相关 | ||
| CTC | 血液 | 根据CTC的不同物理或生物特征进行分离 |
| ctDNA | 血液 | 全外显子或全基因组测序分析特定突变 |
| ctDNA | 血液 | TP53突变、DDR基因等靶向基因测序 |
| ctDNA | 血液 | 采用ddPCR检测AR突变和拷贝数 |
| [1] | World cancer report:cancer research for cancer prevention[EB/OL]. [2020-06-20](2020-07-01). https://publications.iarc.fr/586. |
| [2] |
XI Y, XU P. Global colorectal cancer burden in 2020 and projections to 2040[J]. Transl Oncol, 2021, 14(10):101174.
DOI URL |
| [3] |
SCHRÖDER F H, HUGOSSON J, ROOBOL M J, et al. Screening and prostate-cancer mortality in a randomized European study[J]. N Engl J Med, 2009, 360(13):1320-1328.
DOI URL |
| [4] | 前列腺癌筛查中国专家共识(2021年版)[J]. 中国癌症杂志, 2021, 31(5):435-440. |
| [5] |
GANDAGLIA G, ALBERS P, ABRAHAMSSON P A, et al. Structured population-based prostate-specific antigen screening for prostate cancer:the European Association of Urology Position in 2019[J]. Eur Urol, 2019, 76(2):142-150.
DOI URL |
| [6] |
LOEB S, SANDA M G, BROYLES D L, et al. The prostate health index selectively identifies clinically significant prostate cancer[J]. J Urol, 2015, 193(4):1163-1169.
DOI PMID |
| [7] |
LOEB S. Prostate health index(PHI):golden bullet or just another prostate cancer marker?[J]. Eur Urol, 2013, 63(6):995-997.
DOI URL |
| [8] | BRYANT R J, SJOBERG D D, VICKERS A J, et al. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study[J]. J Natl Cancer Inst, 2015, 107(7):djv095. |
| [9] |
PUNNEN S, NAHAR B, SOODANA-PRAKASH N, et al. Optimizing patient's selection for prostate biopsy:a single institution experience with multi-parametric MRI and the 4Kscore test for the detection of aggressive prostate cancer[J]. PLoS One, 2018, 13(8):e0201384.
DOI URL |
| [10] |
SCHER H I, HELLER G, MOLINA A, et al. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer[J]. J Clin Oncol, 2015, 33(12):1348-1355.
DOI PMID |
| [11] |
LORENTE D, OLMOS D, MATEO J, et al. Decline in circulating tumor cell count and treatment outcome in advanced prostate cancer[J]. Eur Urol, 2016, 70(6):985-992.
DOI PMID |
| [12] |
LORENTE D, OLMOS D, MATEO J, et al. Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts[J]. Ann Oncol, 2018, 29(7):1554-1560.
DOI PMID |
| [13] |
ANTONARAKIS E S, LU C, LUBER B, et al. Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide[J]. J Clin Oncol, 2017, 35(19):2149-2156.
DOI PMID |
| [14] |
ARMSTRONG A J, HALABI S, LUO J, et al. Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer:the PROPHECY study[J]. J Clin Oncol, 2019, 37(13):1120-1129.
DOI URL |
| [15] |
AUTIO K A, DREICER R, ANDERSON J, et al. Safety and efficacy of BIND-014,a docetaxel nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate cancer:a phase 2 clinical trial[J]. JAMA Oncol, 2018, 4(10):1344-1351.
DOI URL |
| [16] |
ANNALA M, VANDEKERKHOVE G, KHALAF D, et al. Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer[J]. Cancer Discov, 2018, 8(4):444-457.
DOI PMID |
| [17] |
GOODALL J, MATEO J, YUAN W, et al. Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition[J]. Cancer Discov, 2017, 7(9):1006-1017.
DOI PMID |
| [18] | WYATT A W, ANNALA M, AGGARWAL R, et al. Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer[J]. J Natl Cancer Inst, 2017, 109(12):djx118. |
| [19] |
DE LAERE B, OEYEN S, MAYRHOFER M, et al. TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer[J]. Clin Cancer Res, 2019, 25(6):1766-1773.
DOI PMID |
| [20] |
CONTEDUCA V, WETTERSKOG D, SHARABIANI M TA, et al. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer:a multi-institution correlative biomarker study[J]. Ann Oncol, 2017, 28(7):1508-1516.
DOI URL |
| [21] | JAYARAM A, WINGATE A, WETTERSKOG D, et al. Plasma androgen receptor copy number status at emergence of metastatic castration-resistant prostate cancer:a pooled multicohort analysis[J]. JCO Precis Oncol, 2019, 3:PO.19.00123. |
| [22] |
SHEN S Y, SINGHANIA R, FEHRINGER G, et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes[J]. Nature, 2018, 563(7732):579-583.
DOI |
| [23] |
WU A, CREMASCHI P, WETTERSKOG D, et al. Genome-wide plasma DNA methylation features of metastatic prostate cancer[J]. J Clin Invest, 2020, 130(4):1991-2000.
DOI PMID |
| [24] |
ZHANG H, FREITAS D, KIM H S, et al. Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation[J]. Nat Cell Biol, 2018, 20(3):332-343.
DOI PMID |
| [25] |
VAGNER T, SPINELLI C, MINCIACCHI V R, et al. Large extracellular vesicles carry most of the tumour DNA circulating in prostate cancer patient plasma[J]. J Extracell Vesicles, 2018, 7(1):1505403.
DOI URL |
| [26] |
THÉRY C, WITWER K W, AIKAWA E, et al. Minimal information for studies of extracellular vesicles 2018(MISEV2018):a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines[J]. J Extracell Vesicles, 2018, 7(1):1535750.
DOI URL |
| [27] |
COLOMBO M, RAPOSO G, THÉRY C. Biogenesis,secretion,and intercellular interactions of exosomes and other extracellular vesicles[J]. Annu Rev Cell Dev Biol, 2014, 30:255-289.
DOI URL |
| [28] |
PELLEGRINI K L, PATIL D, DOUGLAS K J S, et al. Detection of prostate cancer-specific transcripts in extracellular vesicles isolated from post-DRE urine[J]. Prostate, 2017, 77(9):990-999.
DOI PMID |
| [29] |
HESSELS D, KLEIN GUNNEWIEK J M, VAN OORT I, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer[J]. Eur Urol, 2003, 44(1):8-16.
DOI PMID |
| [30] | DE KOK J B, VERHAEGH G W, ROELOFS R W, et al. DD3(PCA3),a very sensitive and specific marker to detect prostate tumors[J]. Cancer Res, 2002, 62(9):2695-2698. |
| [31] |
LENDÍNEZ-CANO G, ALONSO-FLORES J, BELTRÁN-AGUILAR V, et al. Comparison of pathological data between prostate biopsy and radical prostatectomy specimen in patients with low to very low risk prostate cancer[J]. Actas Urol Esp, 2015, 39(8):482-487.
DOI URL |
| [32] |
VAN NESTE L, BIGLEY J, TOLL A, et al. A tissue biopsy-based epigenetic multiplex PCR assay for prostate cancer detection[J]. BMC Urol, 2012, 12:16.
DOI PMID |
| [33] |
VAN NESTE L, HENDRIKS R J, DIJKSTRA S, et al. Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score[J]. Eur Urol, 2016, 70(5):740-748.
DOI PMID |
| [34] |
MCKIERNAN J, DONOVAN M J, MARGOLIS E, et al. A prospective adaptive utility trial to validate performance of a novel urine exosome gene expression assay to predict high-grade prostate cancer in patients with prostate-specific antigen 2-10ng/ml at initial biopsy[J]. Eur Urol, 2018, 74(6):731-738.
DOI PMID |
| [35] |
SREEKUMAR A, POISSON L M, RAJENDIRAN T M, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression[J]. Nature, 2009, 457(7231):910-914.
DOI |
| [36] |
KHAN A P, RAJENDIRAN T M, ATEEQ B, et al. The role of sarcosine metabolism in prostate cancer progression[J]. Neoplasia, 2013, 15(5):491-501.
DOI PMID |
| [37] |
SROKA W D, BOUGHTON B A, REDDY P, et al. Determination of amino acids in urine of patients with prostate cancer and benign prostate growth[J]. Eur J Cancer Prev, 2017, 26(2):131-134.
DOI PMID |
| [38] |
TOMLINS S A, RHODES D R, PERNER S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer[J]. Science, 2005, 310(5748):644-648.
DOI PMID |
| [39] |
HESSELS D, SMIT F P, VERHAEGH G W, et al. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer[J]. Clin Cancer Res, 2007, 13(17):5103-5108.
DOI PMID |
| [40] |
KLEIN E A, COOPERBERG M R, MAGI-GALLUZZI C, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity,tumor multifocality,and biopsy undersampling[J]. Eur Urol, 2014, 66(3):550-560.
DOI URL |
| [41] |
CUZICK J, BERNEY D M, FISHER G, et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort[J]. Br J Cancer, 2012, 106(6):1095-1099.
DOI |
| [42] |
KNUDSEN B S, KIM H L, ERHO N, et al. Application of a clinical whole-transcriptome assay for staging and prognosis of prostate cancer diagnosed in needle core biopsy specimens[J]. J Mol Diagn, 2016, 18(3):395-406.
DOI PMID |
| [43] |
SHIPITSIN M, SMALL C, CHOUDHURY S, et al. Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error[J]. Br J Cancer, 2014, 111(6):1201-1212.
DOI |
| [1] | ZHOU Yunlan, SHEN Lisong. Clinical application and challenges of liquid biopsy biomarkers in non-small cell lung cancer [J]. Laboratory Medicine, 2023, 38(9): 807-811. |
| [2] | SUN Chuanyu, ZHAO Xiaojun, GE Shengyang, ZHANG Yang. Transcription factors in prostate cancer progression [J]. Laboratory Medicine, 2023, 38(9): 818-824. |
| [3] | PENG Wei, LI Yungai, XU Jing, LIU Hua, YANG Cuixia, SHEN Yunyue. Serum inflammatory factors combined with PSA and f-PSA in the auxiliary diagnosis of prostate cancer [J]. Laboratory Medicine, 2023, 38(9): 849-854. |
| [4] | CHEN Wenju, ZHOU Yong, XU Jiajia, WANG Pan. Role of serum exosomal miR-23b-3p and miR-4429 in patients with hepatocellular carcinoma [J]. Laboratory Medicine, 2023, 38(7): 624-628. |
| [5] | ZHANG Min, WANG Binyu, CHI Weiqun, LIU Yu. Research progress of exosomal non-coding RNA as biomarkers for disease diagnosis [J]. Laboratory Medicine, 2023, 38(6): 594-598. |
| [6] | GAO Feng. Clinical application of novel tumor biomarkers：prospects and challenges [J]. Laboratory Medicine, 2023, 38(4): 303-306. |
| [7] | WANG Rui, LI Zhaoyan, ZHAO Aiguang. Application of circulating tumor DNA detection in the diagnosis and treatment of gastric cancer [J]. Laboratory Medicine, 2022, 37(9): 877-881. |
| [8] | DUAN Yuping, XIE Li, CAI Leiming, WU Jingjing, HONG Mao, LI Qian. Correlation of serum exosomes,placental exosomes and exosomal miR-210 with preeclampsia [J]. Laboratory Medicine, 2022, 37(8): 715-719. |
| [9] | LIU Xingqiang, NING Lifen, LI Lin, CHEN Zhongcheng. Correlation of lung cancer clinicopathological characteristics with FR+-CTC,ANXA2 and ProGRP [J]. Laboratory Medicine, 2022, 37(8): 735-740. |
| [10] | YU Qi, SUN Yi, WANG Qiongli, CAI Yiting, LI Li. Application of morphological analysis of circulating tumor cells in clinical examination [J]. Laboratory Medicine, 2022, 37(3): 264-269. |
| [11] | WANG Linlin, XU Lili, FAN Jun, QIAN Yu. Relationship between oxidative stress markers with prostatic hyperplasia and prostate cancer [J]. Laboratory Medicine, 2022, 37(12): 1135-1140. |
| [12] | MENG Jun, WANG Junqing, FEI Xiaochun, GU Zhidong. Establishment and validation of a plasma exosome-derived circular RNA model for HCC diagnosis [J]. Laboratory Medicine, 2022, 37(1): 1-10. |
| [13] | SHEN Suya, HUANG Jianzhao, LI Xiaohuai. Progress on the enrichment technology of circulating tumor cells [J]. Laboratory Medicine, 2022, 37(1): 91-96. |
| [14] | YANG Chaomei, FENG Jie, LANG Lei, YAN Guangtao. Clinical application value of CTC combined determination with CEA and CA125 in colorectal cancer [J]. Laboratory Medicine, 2021, 36(9): 901-905. |
| [15] | QUAN Heng, ZHU Jing, LIAO Huanjin, WU Jun. Role of p2PSA,p2PSA% and PHI in the diagnosis of prostate cancer [J]. Laboratory Medicine, 2021, 36(7): 705-709. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
